Cargando…

Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors

The chromatin reader protein Spindlin1 plays an important role in epigenetic regulation, through which it has been linked to several types of malignant tumors. In the current work, we report on the development of novel analogs of the previously published lead inhibitor A366. In an effort to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Luise, Chiara, Robaa, Dina, Regenass, Pierre, Maurer, David, Ostrovskyi, Dmytro, Seifert, Ludwig, Bacher, Johannes, Burgahn, Teresa, Wagner, Tobias, Seitz, Johannes, Greschik, Holger, Park, Kwang-Su, Xiong, Yan, Jin, Jian, Schüle, Roland, Breit, Bernhard, Jung, Manfred, Sippl, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199216/
https://www.ncbi.nlm.nih.gov/pubmed/34072837
http://dx.doi.org/10.3390/ijms22115910
_version_ 1783707324369600512
author Luise, Chiara
Robaa, Dina
Regenass, Pierre
Maurer, David
Ostrovskyi, Dmytro
Seifert, Ludwig
Bacher, Johannes
Burgahn, Teresa
Wagner, Tobias
Seitz, Johannes
Greschik, Holger
Park, Kwang-Su
Xiong, Yan
Jin, Jian
Schüle, Roland
Breit, Bernhard
Jung, Manfred
Sippl, Wolfgang
author_facet Luise, Chiara
Robaa, Dina
Regenass, Pierre
Maurer, David
Ostrovskyi, Dmytro
Seifert, Ludwig
Bacher, Johannes
Burgahn, Teresa
Wagner, Tobias
Seitz, Johannes
Greschik, Holger
Park, Kwang-Su
Xiong, Yan
Jin, Jian
Schüle, Roland
Breit, Bernhard
Jung, Manfred
Sippl, Wolfgang
author_sort Luise, Chiara
collection PubMed
description The chromatin reader protein Spindlin1 plays an important role in epigenetic regulation, through which it has been linked to several types of malignant tumors. In the current work, we report on the development of novel analogs of the previously published lead inhibitor A366. In an effort to improve the activity and explore the structure–activity relationship (SAR), a series of 21 derivatives was synthesized, tested in vitro, and investigated by means of molecular modeling tools. Docking studies and molecular dynamics (MD) simulations were performed to analyze and rationalize the structural differences responsible for the Spindlin1 activity. The analysis of MD simulations shed light on the important interactions. Our study highlighted the main structural features that are required for Spindlin1 inhibitory activity, which include a positively charged pyrrolidine moiety embedded into the aromatic cage connected via a propyloxy linker to the 2-aminoindole core. Of the latter, the amidine group anchor the compounds into the pocket through salt bridge interactions with Asp184. Different protocols were tested to identify a fast in silico method that could help to discriminate between active and inactive compounds within the A366 series. Rescoring the docking poses with MM-GBSA calculations was successful in this regard. Because A366 is known to be a G9a inhibitor, the most active developed Spindlin1 inhibitors were also tested over G9a and GLP to verify the selectivity profile of the A366 analogs. This resulted in the discovery of diverse selective compounds, among which 1s and 1t showed Spindlin1 activity in the nanomolar range and selectivity over G9a and GLP. Finally, future design hypotheses were suggested based on our findings.
format Online
Article
Text
id pubmed-8199216
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81992162021-06-14 Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors Luise, Chiara Robaa, Dina Regenass, Pierre Maurer, David Ostrovskyi, Dmytro Seifert, Ludwig Bacher, Johannes Burgahn, Teresa Wagner, Tobias Seitz, Johannes Greschik, Holger Park, Kwang-Su Xiong, Yan Jin, Jian Schüle, Roland Breit, Bernhard Jung, Manfred Sippl, Wolfgang Int J Mol Sci Article The chromatin reader protein Spindlin1 plays an important role in epigenetic regulation, through which it has been linked to several types of malignant tumors. In the current work, we report on the development of novel analogs of the previously published lead inhibitor A366. In an effort to improve the activity and explore the structure–activity relationship (SAR), a series of 21 derivatives was synthesized, tested in vitro, and investigated by means of molecular modeling tools. Docking studies and molecular dynamics (MD) simulations were performed to analyze and rationalize the structural differences responsible for the Spindlin1 activity. The analysis of MD simulations shed light on the important interactions. Our study highlighted the main structural features that are required for Spindlin1 inhibitory activity, which include a positively charged pyrrolidine moiety embedded into the aromatic cage connected via a propyloxy linker to the 2-aminoindole core. Of the latter, the amidine group anchor the compounds into the pocket through salt bridge interactions with Asp184. Different protocols were tested to identify a fast in silico method that could help to discriminate between active and inactive compounds within the A366 series. Rescoring the docking poses with MM-GBSA calculations was successful in this regard. Because A366 is known to be a G9a inhibitor, the most active developed Spindlin1 inhibitors were also tested over G9a and GLP to verify the selectivity profile of the A366 analogs. This resulted in the discovery of diverse selective compounds, among which 1s and 1t showed Spindlin1 activity in the nanomolar range and selectivity over G9a and GLP. Finally, future design hypotheses were suggested based on our findings. MDPI 2021-05-31 /pmc/articles/PMC8199216/ /pubmed/34072837 http://dx.doi.org/10.3390/ijms22115910 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Luise, Chiara
Robaa, Dina
Regenass, Pierre
Maurer, David
Ostrovskyi, Dmytro
Seifert, Ludwig
Bacher, Johannes
Burgahn, Teresa
Wagner, Tobias
Seitz, Johannes
Greschik, Holger
Park, Kwang-Su
Xiong, Yan
Jin, Jian
Schüle, Roland
Breit, Bernhard
Jung, Manfred
Sippl, Wolfgang
Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors
title Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors
title_full Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors
title_fullStr Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors
title_full_unstemmed Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors
title_short Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors
title_sort structure-based design, docking and binding free energy calculations of a366 derivatives as spindlin1 inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199216/
https://www.ncbi.nlm.nih.gov/pubmed/34072837
http://dx.doi.org/10.3390/ijms22115910
work_keys_str_mv AT luisechiara structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT robaadina structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT regenasspierre structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT maurerdavid structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT ostrovskyidmytro structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT seifertludwig structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT bacherjohannes structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT burgahnteresa structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT wagnertobias structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT seitzjohannes structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT greschikholger structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT parkkwangsu structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT xiongyan structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT jinjian structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT schuleroland structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT breitbernhard structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT jungmanfred structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors
AT sipplwolfgang structurebaseddesigndockingandbindingfreeenergycalculationsofa366derivativesasspindlin1inhibitors